LFST LifeStance Health Group, Inc.

Nasdaq lifestance.com


$ 5.20 $ 0.10 (1.96 %)    

Wednesday, 15-Oct-2025 15:59:57 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 5.19
$ 5.09
$ 5.19 x 250
$ 5.39 x 3,300
$ 5.07 - $ 5.22
$ 3.74 - $ 8.61
952,868
na
2.02B
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-10-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-17-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-buy-on-lifestance-health-gr-raises-price-target-to-9

UBS analyst Kevin Caliendo maintains LifeStance Health Gr (NASDAQ:LFST) with a Buy and raises the price target from $8.5 to $9.

 lifestance-health-gr-affirms-fy2025-sales-guidance-of-1400b-1440b-vs-1413b-est

2025 GuidanceLifeStance is providing the following outlook for 2025:The Company is reiterating full year revenue of $1.40 billi...

 ubs-upgrades-lifestance-health-gr-to-buy-announces-85-price-target

UBS analyst Kevin Caliendo upgrades LifeStance Health Gr (NASDAQ:LFST) from Neutral to Buy and announces $8.5 price target.

 lifestance-health-gr-sees-q2-sales-332000m-352000m-vs-35276m-est

LifeStance Health Gr (NASDAQ:LFST) sees Q2 sales of $332.000 million-$352.000 million vs $352.76 million analyst estimate.

 lifestance-health-gr-affirms-fy2025-sales-guidance-of-140b-144b-vs-142b-est

LifeStance Health Gr (NASDAQ:LFST) affirms FY2025 sales outlook from $1.40 billion-$1.44 billion to $1.40 billion-$1.44 billion...

 lifestance-health-gr-q1-sales-33297m-beat-33290m-estimate

LifeStance Health Gr (NASDAQ:LFST) reported quarterly sales of $332.97 million which beat the analyst consensus estimate of $33...

 keybanc-initiates-coverage-on-lifestance-health-gr-with-overweight-rating-announces-price-target-of-9

Keybanc analyst Steve Dechert initiates coverage on LifeStance Health Gr (NASDAQ:LFST) with a Overweight rating and announc...

 canaccord-genuity-initiates-coverage-on-lifestance-health-gr-with-buy-rating-announces-price-target-of-8

Canaccord Genuity analyst Richard Close initiates coverage on LifeStance Health Gr (NASDAQ:LFST) with a Buy rating and annou...

 lifestance-health-gr-q4-2024-gaap-eps-001-beats-004-estimate-sales-32550m-beat-31372m-estimate

LifeStance Health Gr (NASDAQ:LFST) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of ...

 lifestance-names-dave-bourdon-as-ceo-ken-burdick-named-as-executive-chairman

Bourdon, who joined LifeStance as Chief Financial Officer in 2022, is succeeding Ken Burdick, who is retiring from his role as ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION